Pharmacoeconomic comparison of an albumin-furosemide complex versus sequential therapy for renal insufficiency.
The purpose of this economic analysis was to develop an economic model using intra-institutional cost data for acute, oliguric renal insufficiency treated with either an albumin-furosemide complex or albumin followed by furosemide (sequential therapy). The perspective of this study was from the standpoint of the institution (University Medical Center, a teaching hospital). The decision tree and sensitivity analyses demonstrated that the albumin-furosemide complex would be more effective and less costly than sequential therapy for a range of outcome probabilities. Using effectiveness assumptions from published literature, the complex could avoid dialysis in 27% of patients compared with 8% of patients receiving sequential therapy. The complex would also be less costly ($7778 vs $8748). In terms of cost-effectiveness, the complex is $28,807 per averted dialysis compared with $109,350 for sequential therapy.
Erstad
B L
BL
Department of Pharmacy Practice and Science, University of Arizona, Tucson 85721-0207, USA.
D000208:Acute Disease / Q000191:economics / Q000628:therapy; D003131:Combined Modality Therapy / Q000191:economics; D003365:Costs and Cost Analysis; D003956:Dialysis / Q000191:economics; D004232:Diuretics / Q000191:economics / Q000627:therapeutic use; D005665:Furosemide / Q000627:therapeutic use*; D006801:Humans; D018803:Models, Economic; D009846:Oliguria / Q000188:drug therapy* / Q000191:economics; D051437:Renal Insufficiency / Q000188:drug therapy* / Q000191:economics*; D012709:Serum Albumin / Q000627:therapeutic use*; D016896:Treatment Outcome
D004232:Diuretics; D012709:Serum Albumin; D005665:Furosemide